MYGN Myriad Genetics: Company Short-Term Debts

Symbol and logo of brand Myriad Genetics Corp (MYGN)

Myriad Genetics, Inc. (MYGN) is a recognized authority in preventive oncology, with trust among medical professionals built on the flawless accuracy of its forecasts. This chart on GURU.Markets, illustrating the price evolution of the stock, shows the metric at 0.02. Myriad Genetics, Inc. (MYGN) dominates the genetics niche thanks to exclusive DNA information arrays and MyRisk. High efficiency is maintained through the modernization of automated laboratories operating at maximum capacity.

MYGN Myriad Genetics Inc Company Short-Term Loans and Borrowings (07/04/2022 - 10/31/2026)

Summary analytical data breakdowns for Myriad (MYGN)

- stock price and consensus target price:
Stock Price Myriad Genetics|MYGN - Consensus Target
- company stock capitalization data:
Market Capitalization Myriad Genetics, Inc.|MYGN - Total Enterprise Value
- business book valuation details:
Net Assets per Single Share Myriad Genetics|MYGN - Accounting Value of Company|Market Cap to Net Assets Ratio myriad.com|MYGN - Aggregate Asset Value
- debt and liquidity details:
Total Debt to Capital Myriad Genetics, Inc.|MYGN - Long-Term Debt to Capital|Short-Term Debt to Equity Myriad Genetics, Inc.|MYGN - Company Aggregate Debt|Debts to Book Capitalization Myriad Genetics, Inc.|MYGN - Company Long-Term Debts|Company Short-Term Debt Myriad Genetics|Quick Liquidity Indicator myriad.com
- earnings and multiples data:
MYGN - Company Net Income
Fundamental valuation:Myriad Genetics (MYGN)
Manufactured products of Myriad Genetics, Inc.

Short-term debt reflects the total obligations of Myriad Genetics, Inc. (MYGN) with a maturity of up to one year. This metric aggregates current loans and accounts payable, determining the immediate pressure on liquidity. By analyzing the volume of short-term accounts payable and loans, an investor assesses the risk of cash flow gaps. For Myriad Genetics, Inc. (MYGN), this indicator is critical when financing new proprietary tests. Payment stability allows the company to effectively resist the expansion of low-cost sequencing platforms.

Competitors of Myriad Genetics, Inc. (MYGN)

Caris Life Sciences - Company Short-Term Debts|Guardant Health Inc (GH) - Company Current Liabilities|VCYT: Company Short-Term Debts|Short-Term Debt Celcuity Therapeutics (CELC)|Company Short-Term Debt GRAIL, Inc.|CSTL: Company Short-Term Loans and Borrowings|Company Current Liabilities BNR (Burning Rock)|VNRX (volition.com) - Company Short-Term Loans and Borrowings|Company Short-Term Debts BDSX (Biodesix Corp)|Company Short-Term Debts Precipio Inc PRPO|CHEK - Company Short-Term Debt|MYNZ (mainzbiomed.com) - Company Short-Term Indebtedness|OCX: Company Short-Term Debts